Target is the company’s common shares, total number acquired 86,100 shares, total acquisition amount 275,410,500 yen, period 2026\/10\/1-2026\/10\/31, method market purchase. For reference, cumulative total under the previous resolution is 412,000 shares, total amount 1,330,313,500 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Mochida Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4534-20261102-01.pdf","jir_short_summary":"Target is the company's common shares, total number acquired 86,100 shares, total acquisition amount 275,410,500 yen, period 2026\/10\/1-2026\/10\/31, method market purchase. For reference, cumulative total under the previous resolution is 412,000 shares, total amount 1,330,313,500 yen.","jir_summary":"### Current Status of Treasury Stock Acquisition\nThe Company continues its treasury stock acquisition program and, in this instance, conducted market purchases of common shares targeting 86,100 shares with a total acquisition amount of 275,410,500 yen. The acquisition period was from October 1, 2026 to October 31, 2026, and the cumulative number of acquired shares stood at 412,000 shares as of October 31, 2026. At the time of the previous board resolution, an upper limit of 530,000 shares (1.50% of total outstanding shares) and a total amount of 2,000,000,000 yen were established, with the period set from May 18, 2026 to December 18, 2026.\n\n### Impact on Investors and Future Outlook\nTreasury stock acquisition is positioned as part of efforts to improve capital efficiency and return value to shareholders, and may contribute to enhancing shareholder value by mitigating dilution. The latest acquisition status is subject to market conditions, and some or all planned acquisitions may not be executed; therefore, continued attention to future acquisition activity is required.","jir_financial_highlights":"Number of shares acquired (target): 86,100 shares (Unknown)\nTotal amount of acquisition cost: 275,410,500 yen (Unknown)\nAcquisition period: October 1, 2026\uff5eOctober 31, 2026 (Unknown)\nAcquisition method: Market purchases on the Tokyo Stock Exchange (Unknown)\nCumulative number of shares acquired (as of 2026\/10\/31): 412,000 shares (Compared with cumulative total at the previous resolution)","jir_category":"","jir_hashtags":"","jir_key_figures":"86,100 shares: Number of shares acquired\n275,410,500 yen: Total acquisition amount\nOctober 1, 2026\uff5eOctober 31, 2026: Acquisition period\n412,000 shares: Cumulative number of shares acquired (as of 2026\/10\/31)","jir_meta_title":"Mochida Pharmaceutical Co., Ltd. - Notice of Treasury Stock Acquisition Status | November 2026","jir_meta_description":"Mochida Pharmaceutical Co., Ltd. discloses the status of its treasury stock acquisitions, including number of shares acquired, total amount, period and method, along with cumulative figures under the previous resolution. Review the company's shareholder value initiatives.","jir_og_title":"Mochida Pharmaceutical Co., Ltd. - Notice of Treasury Stock Acquisition Status | November 2026","jir_og_description":"Mochida Pharmaceutical Co., Ltd. announces progress of its treasury stock acquisitions. Key points include number of shares acquired, total amount, period, and method. Previous cumulative figures are also provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-139584","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n